July 17, 2026

FDA Approves New Iohexol Vials

The approval includes additional 300 mg iodine/mL and 350 mg iodine/mL vial presentations.

Conexiant

July 16, 2026

A Sales Tax on Doctor Visits and Medicine? In Missouri, Some Worry

Voters will decide whether to expand lawmakers' authority to tax currently exempt healthcare goods and services, raising concerns about patient costs and healthcare access.

Kff Health News

July 15, 2026

Breastfeeding May Help Infants Achieve Adequate Sleep

A nationwide birth cohort found lower odds of short sleep at 1 year among infants breastfed during the first 6 months of life, regardless of formula supplementation.

Conexiant

July 14, 2026

Autism Spectrum Disorder Linked to Distinct Urine Metabolite Pattern

Researchers proposed a new autism spectrum disorder phenotype characterized by elevated urinary microbially derived metabolites.

Conexiant

July 10, 2026

10 CMS and FDA Actions Affecting Care in 2026

From Medicare payment updates to drug approvals and device access, these federal actions may affect reimbursement, prescribing, patient access, and clinical workflows.

Conexiant

July 09, 2026

Top 10 CDC Updates Physicians Should Know

Recent CDC advisories, testing updates, and immunization recommendations highlight developments in infectious diseases, immunization, and diagnostic testing relevant to physicians across multiple specialties.

Conexiant

July 09, 2026

Connected Health May Match In-Person AD Care

A randomized clinical trial found that a team-based connected health model achieved equivalent improvements in atopic dermatitis severity and symptoms compared with conventional in-person care over 12 months.

Conexiant

July 07, 2026

May Clearing Nasal Viruses Improve Allergic Rhinitis?

A phase 2 randomized trial suggests reducing nasal commensal viruses with ribavirin spray may improve allergic rhinitis symptoms while supporting a proposed disease mechanism.

Conexiant

July 02, 2026

FDA Expands Gene Therapy for Younger Patients

Exagamglogene autotemcel is now indicated for patients aged 2 years and older with sickle cell disease and recurrent vaso-occlusive crises or transfusion-dependent beta thalassemia.

Conexiant

June 30, 2026

FDA Expands Pediatric Roflumilast Use

The expanded indication is supported by pharmacokinetic, safety, tolerability, exploratory efficacy, and long-term safety data from studies in children aged 2 to 5 years.

Conexiant